Efficiency of carvedilol in the protection of Anthracycline-induced cardiomyophy in cancer patients undergoing chemotheraphy compared with control group
Not Applicable
- Conditions
- C00-C97Cancer.Malignant Neoplasms
- Registration Number
- IRCT2014121213090N2
- Lead Sponsor
- Vice Chancellor for research of Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Cancer patients; 18-70 years old; newly diagnosed; candidate for antracyclin therapy. Exclusion criteria: history of myocardial infarction; coronary artery disease; LVEF<50%; significant valvular heart disease; history of congestive heart failure; sinus bradycardia, complete heart block, systolic blood pressure less than 90 mmHg.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiomyopathy. Timepoint: Before treatment,6 months later. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method evel of cardiac Troponin-I. Timepoint: One month after treatment. Method of measurement: Venopuncture.